Portola Pharmaceuticals announced that it has raised $46 million in series B financing that will be used to develop the company's cardiovascular therapies, specifically, moving an oral Factor Xa inhibitor into phase II trials. The round was led by Advanced Technology Ventures (ATV) and Alta Partners. As a result of the financing, Jean George of ATV and Farah Champsi of Alta Partners will be joining the board of directors. Release